Pleomorphic liposarcoma
MONDO:0020562Pleomorphic liposarcoma (PLS), the rarest subtype of liposarcoma (LS), is an aggressive, fast growing tumor located usually in the deep soft tissues of the lower and upper extremities. It is characterized by a variable number of pleomorphic lipoblasts and, in contrast to dedifferentiated liposarcoma, it lacks any association with well-differentiated liposarcoma.
Also known as: PLS, pleomorphic liposarcoma, pleomorphic liposarcoma (morphologic abnormality), PLLS
2820 clinical trials for this condition and its sub-types, 8 tagged with Pleomorphic liposarcoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
New drug duo aims to halt rare cancer's growth
Disease control Recruiting nowThis study tests whether combining two drugs, mirdametinib and palbociclib, can safely slow or stop advanced liposarcoma (a rare soft-tissue cancer). About 54 adults with liposarcoma that has spread or cannot be removed will receive different doses to find the best one. The main …
Phase 1/2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New hope for rare childhood cancer: drug cocktail aims to shrink tumors and prevent return
Disease control Recruiting nowThis study is for children and young adults (up to age 30) with a rare type of soft tissue cancer called non-rhabdomyosarcoma. It tests whether adding the drugs pazopanib and selinexor to standard chemotherapy can improve outcomes. Participants receive treatment tailored to their…
Phase 1/2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Immune booster drug tested on rare cancers
Disease control Recruiting nowThis study is testing a drug called pembrolizumab in people with ultra-rare sarcomas, a group of very uncommon cancers. The drug works by releasing the immune system's brakes so it can attack cancer cells. Researchers want to see if it can shrink tumors or stop them from growing,…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
New combo therapy aims to shrink sarcomas
Disease control Recruiting nowThis early-stage trial tests whether giving a targeted drug (palbociclib) before immunotherapy (pembrolizumab) is safe and can help shrink tumors in people with certain soft tissue sarcomas. About 8 participants will receive the combination. The main goal is to check for side eff…
Phase 1 • Sponsor: John Rieth • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Proton beam boost: new hope for inoperable sarcomas?
Disease control Recruiting nowThis study tests whether a higher dose of proton radiation can better control inoperable soft tissue sarcomas without increasing side effects. Forty adults with these rare tumors will receive targeted radiation over 4 weeks. Researchers will also look at blood and imaging markers…
Phase 2 • Sponsor: Oslo University Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New hope for sarcoma patients: immunotherapy plus chemo shows promise
Disease control Recruiting nowThis study tests a new combination of drugs (tislelizumab, liposomal doxorubicin, and ifosfamide) as a first treatment for people with advanced soft tissue sarcoma that cannot be removed by surgery or has spread. The goal is to see if this combo shrinks tumors and is safe. About …
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC